Crinetics Pharmaceuticals... (CRNX)
Crinetics Pharmaceuticals Statistics
Share Statistics
Crinetics Pharmaceuticals has 93.05M shares outstanding. The number of shares has increased by 17.99% in one year.
| Shares Outstanding | 93.05M |
| Shares Change (YoY) | 17.99% |
| Shares Change (QoQ) | 0.34% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 86.62M |
| Failed to Deliver (FTD) Shares | 1.95K |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 7.17M, so 7.73% of the outstanding shares have been sold short.
| Short Interest | 7.17M |
| Short % of Shares Out | 7.73% |
| Short % of Float | 8.25% |
| Short Ratio (days to cover) | 7.05 |
Valuation Ratios
The PE ratio is -13.84 and the forward PE ratio is -9.83. Crinetics Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -13.84 |
| Forward PE | -9.83 |
| PS Ratio | 3975.39 |
| Forward PS | 2.4 |
| PB Ratio | 3.12 |
| P/FCF Ratio | -17.97 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Crinetics Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.04, with a Debt / Equity ratio of 0.04.
| Current Ratio | 23.04 |
| Quick Ratio | 23.04 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.23 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $2.38K |
| Profits Per Employee | $-682.86K |
| Employee Count | 437 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -33.5% in the last 52 weeks. The beta is 0.58, so Crinetics Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.58 |
| 52-Week Price Change | -33.5% |
| 50-Day Moving Average | 35.85 |
| 200-Day Moving Average | 48.22 |
| Relative Strength Index (RSI) | 31.91 |
| Average Volume (20 Days) | 1.18M |
Income Statement
In the last 12 months, Crinetics Pharmaceuticals had revenue of 1.04M and earned -298.41M in profits. Earnings per share was -3.69.
| Revenue | 1.04M |
| Gross Profit | 1.04M |
| Operating Income | -338.85M |
| Net Income | -298.41M |
| EBITDA | -338.85M |
| EBIT | -338.85M |
| Earnings Per Share (EPS) | -3.69 |
Balance Sheet
The company has 264.55M in cash and 51.72M in debt, giving a net cash position of 212.82M.
| Cash & Cash Equivalents | 264.55M |
| Total Debt | 51.72M |
| Net Cash | 212.82M |
| Retained Earnings | -952.11M |
| Total Assets | 1.43B |
| Working Capital | 1.32B |
Cash Flow
In the last 12 months, operating cash flow was -225.97M and capital expenditures -3.84M, giving a free cash flow of -229.81M.
| Operating Cash Flow | -225.97M |
| Capital Expenditures | -3.84M |
| Free Cash Flow | -229.81M |
| FCF Per Share | -2.84 |
Margins
Gross margin is 100%, with operating and profit margins of -32613.47% and -28720.69%.
| Gross Margin | 100% |
| Operating Margin | -32613.47% |
| Pretax Margin | -28720.69% |
| Profit Margin | -28720.69% |
| EBITDA Margin | -32613.47% |
| EBIT Margin | -32613.47% |
| FCF Margin | -22118.77% |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CRNX is $73.5, which is 140.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $73.5 |
| Price Target Difference | 140.3% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 16.45 |
| Piotroski F-Score | 2 |